ARDS - アリディス・ファ―マシュ―ティカルズ (Aridis Pharmaceuticals Inc.) アリディス・ファ―マシュ―ティカルズ

 ARDSのチャート


 ARDSの企業情報

symbol ARDS
会社名 Aridis Pharmaceuticals Inc (アリディス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aridis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies such as rise in drug resistance short duration of response negative impact on the human microbiome and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections primarily hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its lead product candidate AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M mAb targeting P. aeruginosa serotype O11.   アリディス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、感染症に対する免疫療法の開発・商業化に従事する。完全ヒトモノクロナ―ル抗体を用いて、薬物耐性や短い薬効時間、ヒトのミクロバイオ―ムへの悪影響などの治療の欠点を克服するように設計され、同社の差別化抗体発見プラットフォ―ムを使用する。本社所在地はカリフォルニア州サンノゼ。   Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.
本社所在地 5941 Optical Ct. San Jose CA 95138 USA
代表者氏名
代表者役職名
電話番号 +1 408-385-1742
設立年月日 2003年
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数 30人
url www.aridispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ards
adr_tso
EBITDA EBITDA(百万ドル) -21.68200
終値(lastsale) 12.8254
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 100.48690
売上高 売上高(百万ドル) 1.16000
企業価値(EV) 企業価値(EV)(百万ドル) 161.21890
当期純利益 当期純利益(百万ドル) -22.02800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aridis Pharmaceuticals Inc revenues increased from $44K to $344K. Net loss applicable to common stockholders decreased 35% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $4.6M (expense) to $3M (income).

 ARDSのテクニカル分析


 ARDSのニュース

   Aridis, Galapagos lead healthcare gainers; Epizyme, Cue Biopharma among losers  2022/01/27 15:03:00 Seeking Alpha
Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.
   Aridis Shares Rise On Funding For Inhaled Monoclonal Antibodies Against Influenza, COVID-19  2022/01/27 13:03:53 Benzinga
The Bill & Melinda Gates Foundation has granted $1.9 million to Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) to evaluate Aridis'' inhaled monoclonal antibodies (mAbs) against influenza and COVID-19 for low- and middle-income countries. The mAbs will be manufactured using a spirulina-based platform technology developed by Lumen Bioscience. Lumen Bio''s platform can produce therapeutic proteins at lower costs than conventional Full story available on Benzinga.com
   HOFV, VYNT and ONE among mid-day movers  2022/01/24 17:45:45 Seeking Alpha
Gainers: Exterran EXTN +51%.Aridis Pharmaceuticals (ARDS) +36%.Kohl''s KSS +31%.ShiftPixy PIXY +31%.G Medical Innovations GMVD +14%.Hall of Fame (HOFV) +14%.Shineco SISI +12%.Atlas…
   Aridis Pharmaceuticals Inc Shares Close the Week 26.9% Lower - Weekly Wrap  2022/01/11 23:40:19 Kwhen Finance
Aridis Pharmaceuticals Inc (ARDS) shares closed this week 26.9% lower than it did at the end of last week. The stock is currently down 28.1% year-to-date, down 73.2% over the past 12 months, and down 87.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $2.32 and as low as $1.56 this week.Trading volume this week was 11.4% lower than the 10-day average and 83.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1434.7% The company's stock price performance over the past 12 months lags the peer average by 710.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aridis Pharmaceuticals Inc Shares Close the Day 11.8% Lower - Daily Wrap  2022/01/09 04:08:08 Kwhen Finance
Aridis Pharmaceuticals Inc (ARDS) shares closed today 11.8% lower than it did at the end of yesterday. The stock is currently down 26.2% year-to-date, down 71.3% over the past 12 months, and down 86.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $2.42 and as low as $1.69 this week.Shares closed 79.7% below its 52-week high and 1.8% above its 52-week low.Trading volume this week was 59.3% lower than the 10-day average and 84.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 9946.0% The company's stock price performance over the past 12 months lags the peer average by 715.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aridis Pharmaceuticals Inc Shares Fall 2.6% Below Previous 52-Week Low - Market Mover  2021/10/06 08:47:04 iShook Finance
Aridis Pharmaceuticals Inc (ARDS) shares closed 2.6% lower than its previous 52 week low, giving the company a market cap of $41M. The stock is currently down 43.3% year-to-date, down 54.1% over the past 12 months, and down 73
   Aridis Pharmaceuticals EPS beats by $0.14, misses on revenue  2021/08/12 13:14:01 Seeking Alpha
   Aridis Pharmaceuticals'' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)  2021/07/26 12:30:00 PR Newswire
LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by
   Aridis Acquires Rights For Development And Commercialization Of Suvratoxumab  2021/07/19 13:10:00 FinanzNachrichten
LONDON (dpa-AFX) - Aridis Pharmaceuticals Inc. (ARDS) said that it has acquired global exclusive rights from AstraZeneca (AZN, AZN.L) for development and commercialization of the late stage monocl
   Allied Healthcare Products, SCWorx leads healthcare gainers; Meridian Bioscience, Aridis Pharmaceuticals among major losers  2021/07/13 15:10:08 Seeking Alpha
   Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright  2021/05/14 10:37:48 Smarter Analyst
In a report released today, Vernon Bernardino from H.C. The post Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .
   Aridis Pharmaceuticals EPS misses by $0.17  2021/05/11 20:42:49 Seeking Alpha
   Aridis Pharmaceuticals Inc. Shares Close the Day 21.2% Higher - Daily Wrap  2021/03/11 22:30:00 Kwhen Finance
Aridis Pharmaceuticals Inc. shares closed today 21.2% higher than it did at the end of yesterday. The stock is currently up 27.2% year-to-date, up 47.0% over the past 12 months, and down 40.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.9%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $7.73 and as low as $5.56 this week.Shares closed 2e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 79.2% lower than the 10-day average and 75.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -53.8% The company's stock price performance over the past 12 months lags the peer average by -66.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aridis Pharmaceuticals Inc. Shares Close the Day 12.5% Higher - Daily Wrap  2021/03/05 22:30:00 Kwhen Finance
Aridis Pharmaceuticals Inc. shares closed today 12.5% higher than it did at the end of yesterday. The stock is currently down 8.7% year-to-date, down 13.0% over the past 12 months, and down 57.4% over the past five years. Today, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 fell 0.5%. Trading Activity Shares traded as high as $6.65 and as low as $4.70 this week.Shares closed 4e+1% below its 52-week high and 6e+1% above its 52-week low.Trading volume this week was 46.9% higher than the 10-day average and 13.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -127.2% The company's stock price performance over the past 12 months lags the peer average by -121.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリディス・ファ―マシュ―ティカルズ ARDS Aridis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)